JP7797382B2 - がん診断 - Google Patents

がん診断

Info

Publication number
JP7797382B2
JP7797382B2 JP2022524045A JP2022524045A JP7797382B2 JP 7797382 B2 JP7797382 B2 JP 7797382B2 JP 2022524045 A JP2022524045 A JP 2022524045A JP 2022524045 A JP2022524045 A JP 2022524045A JP 7797382 B2 JP7797382 B2 JP 7797382B2
Authority
JP
Japan
Prior art keywords
cancer
markers
protein
subject
expression
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2022524045A
Other languages
English (en)
Japanese (ja)
Other versions
JP2023500819A5 (https=
JP2023500819A (ja
Inventor
リチャード ロブ，
アンドレアス メラー，
Original Assignee
ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from AU2019904005A external-priority patent/AU2019904005A0/en
Application filed by ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ filed Critical ザ・カウンシル・オヴ・ザ・クイーンズランド・インスティテュート・オヴ・メディカル・リサーチ
Publication of JP2023500819A publication Critical patent/JP2023500819A/ja
Publication of JP2023500819A5 publication Critical patent/JP2023500819A5/ja
Application granted granted Critical
Publication of JP7797382B2 publication Critical patent/JP7797382B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/5758—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites
    • G01N33/57585—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumours, cancers or neoplasias, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides or metabolites involving compounds identifiable in body fluids
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57557—Immunoassay; Biospecific binding assay; Materials therefor for cancer of other specific parts of the body, e.g. brain
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6803—General methods of protein analysis not limited to specific proteins or families of proteins
    • G01N33/6848—Methods of protein analysis involving mass spectrometry
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/52—Predicting or monitoring the response to treatment, e.g. for selection of therapy based on assay results in personalised medicine; Prognosis
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/54—Determining the risk of relapse
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/56—Staging of a disease; Further complications associated with the disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/60—Complex ways of combining multiple protein biomarkers for diagnosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Chemical & Material Sciences (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Biochemistry (AREA)
  • Pathology (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Microbiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Bioinformatics & Computational Biology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Spectroscopy & Molecular Physics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
JP2022524045A 2019-10-24 2020-10-26 がん診断 Active JP7797382B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
AU2019904005 2019-10-24
AU2019904005A AU2019904005A0 (en) 2019-10-24 A cancer diagnostic
PCT/AU2020/051155 WO2021077181A1 (en) 2019-10-24 2020-10-26 A cancer diagnostic

Publications (3)

Publication Number Publication Date
JP2023500819A JP2023500819A (ja) 2023-01-11
JP2023500819A5 JP2023500819A5 (https=) 2023-11-06
JP7797382B2 true JP7797382B2 (ja) 2026-01-13

Family

ID=75619520

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2022524045A Active JP7797382B2 (ja) 2019-10-24 2020-10-26 がん診断

Country Status (8)

Country Link
US (1) US20220365089A1 (https=)
EP (1) EP4049027A4 (https=)
JP (1) JP7797382B2 (https=)
KR (1) KR20220092902A (https=)
CN (1) CN115380215B (https=)
AU (1) AU2020370867A1 (https=)
CA (1) CA3158472A1 (https=)
WO (1) WO2021077181A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116466085A (zh) * 2022-11-28 2023-07-21 中国人民解放军海军军医大学第三附属医院 一种四基因的生物标志物组合及其在肝癌治疗中的应用
WO2025050605A1 (en) * 2023-09-05 2025-03-13 The University Of Hong Kong Nidogen 1 as a diagnostic marker and therapeutic target of hepatocellular carcinoma, composition and methods thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013022995A2 (en) 2011-08-08 2013-02-14 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarker compositions and methods
WO2016195051A1 (ja) 2015-05-29 2016-12-08 国立研究開発法人国立がん研究センター 膵がんを診断するための血漿バイオマーカーパネル
WO2018079689A1 (ja) 2016-10-28 2018-05-03 公益財団法人がん研究会 バイオマーカー、疾患関連遺伝子の探索方法、及び腎がんマーカー
WO2018094469A1 (en) 2016-11-24 2018-05-31 The Council Of The Queensland Institute Of Medical Research Determining a cancer prognosis
WO2019109077A1 (en) 2017-12-01 2019-06-06 Cornell University Nanoparticles and distinct exosome subsets for detection and treatment of cancer

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2886607A1 (en) * 2012-10-17 2014-04-24 Cedars-Sinai Medical Center Molecular signatures of ovarian cancer
CN106188244B (zh) * 2015-05-29 2019-12-27 王育民 抑制癌细胞活性的短肽治疗剂及含有它的医药组合物
US12123058B2 (en) * 2018-01-25 2024-10-22 Sorbonne Universite Molecular signature and use thereof for the identification of indolent prostate cancer

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013022995A2 (en) 2011-08-08 2013-02-14 Caris Life Sciences Luxembourg Holdings, S.A.R.L. Biomarker compositions and methods
JP2014522993A (ja) 2011-08-08 2014-09-08 カリス ライフ サイエンシズ ルクセンブルク ホールディングス エス．アー．エール．エル． バイオマーカー組成物および方法
WO2016195051A1 (ja) 2015-05-29 2016-12-08 国立研究開発法人国立がん研究センター 膵がんを診断するための血漿バイオマーカーパネル
WO2018079689A1 (ja) 2016-10-28 2018-05-03 公益財団法人がん研究会 バイオマーカー、疾患関連遺伝子の探索方法、及び腎がんマーカー
WO2018094469A1 (en) 2016-11-24 2018-05-31 The Council Of The Queensland Institute Of Medical Research Determining a cancer prognosis
WO2019109077A1 (en) 2017-12-01 2019-06-06 Cornell University Nanoparticles and distinct exosome subsets for detection and treatment of cancer

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Jianlu Song，Cell adhesion-related gene somatic mutations are enriched in aggressive papillary thyroid microcarcinomas，J Transl Med，2018年，16:269，pp.1-9，https://doi.org/10.1186/s12967-018-1642-0

Also Published As

Publication number Publication date
EP4049027A4 (en) 2024-02-07
US20220365089A1 (en) 2022-11-17
KR20220092902A (ko) 2022-07-04
CN115380215A (zh) 2022-11-22
WO2021077181A1 (en) 2021-04-29
CA3158472A1 (en) 2021-04-29
EP4049027A1 (en) 2022-08-31
CN115380215B (zh) 2026-03-17
AU2020370867A1 (en) 2022-06-09
JP2023500819A (ja) 2023-01-11

Similar Documents

Publication Publication Date Title
US20250116669A1 (en) Determining a Cancer Prognosis
US12209286B2 (en) Methods of diagnosing, determining the progression of, and treating a prostate cancer
JP7797382B2 (ja) がん診断
KR102903049B1 (ko) 치료에 대한 암 반응 결정
US10359426B2 (en) Use of isocitrate dehydrogenase 1 as a diagnostic and prognostic biomarker and therapeutic target for lung cancers
JP7453284B2 (ja) 癌のバイオマーカーとしてのｐｄ－ｅｃｇｆ
HK40084721A (en) A cancer diagnostic
JP2014095643A (ja) 炎症性疾患治療薬のスクリーニング方法、並びに炎症性疾患の治療及び検査
EP2966448B1 (en) Method for the prediction or prognosis of the response of a human subject suffering from cancer to treatment with an antagonist of the nk1 receptor
HK40049121A (en) Methods for detecting prostate cancer
US20190064172A1 (en) Prognosis of serous ovarian cancer using biomarkers

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20231026

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20231026

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20240731

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20240806

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241106

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20241226

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250205

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20250401

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250701

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20250901

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251001

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20251209

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20251224

R150 Certificate of patent or registration of utility model

Ref document number: 7797382

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150